110 patents
Page 5 of 6
Utility
Methods for Treating Depressive Symptoms
6 Jan 21
The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof.
Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
Filed: 25 Jun 20
Utility
Single chain Fc fusion proteins
4 Jan 21
The present invention provides novel, single chain Fc fusion proteins having improved properties.
Juan Alvarez, Demetri T. Moustakas, Heather R. Brodkin, Leslie A. McSweeney
Filed: 9 Apr 18
Utility
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
30 Dec 20
Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
Filed: 13 Sep 20
Utility
Polymer-based Sustained Release Device
16 Dec 20
This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides.
Steven G. Wright, Troy Christensen, Thean Yeoh, Michael E. Rickey, Joyce M. Hotz, Rajesh Kumar, Henry R. Costantino
Filed: 21 Jan 20
Utility
Morphinan Derivatives with High Oral Bioavailability
9 Dec 20
Ryan Turncliff, Daniel Deaver, Derrick Arnelle
Filed: 9 Jan 20
Utility
Aripiprazole prodrug composition
30 Nov 20
Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug.
Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
Filed: 28 Jun 18
Utility
Prodrugs of Fumarates and Their Use in Treating Various Diseases
11 Nov 20
Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
Filed: 13 Feb 20
Utility
Morphinan Derivatives for the Treatment of Drug Overdose
4 Nov 20
Bernard Silverman, Fen-Ni Fu, Chengyun Guo
Filed: 6 Feb 20
Utility
Heterocyclic compounds for the treatment of neurological and psychological disorders
2 Nov 20
Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
Filed: 28 May 19
Utility
Sustained Release Aminopyridine Composition
28 Oct 20
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Sean Cunningham, Seamus Mulligan, Michael Myers
Filed: 9 Jul 20
Utility
Aripiprazole formulations having increased injection speeds
26 Oct 20
The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Magali B. Hickey, Jennifer Vandiver
Filed: 7 Feb 19
Utility
Thienothiophene compounds for long-acting injectable compositions and related methods
19 Oct 20
The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof.
Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
Filed: 10 Jul 19
Utility
Compositions of buprenorphine and μ antagonists
19 Oct 20
Daniel R. Deaver, Elliot Ehrich
Filed: 24 Apr 19
Utility
Naphthylenyl compounds for long-acting injectable compositions and related methods
12 Oct 20
The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof.
Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
Filed: 10 Jul 19
Utility
Aripiprazole Prodrug Composition
7 Oct 20
Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (h) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug.
Philip CRESSWELL, Magali HICKEY, Kristopher PERKIN, Greg SMITH, Elaine LIVERSIDGE, Brian STEINBERG, David MANSER, Tarek ZEIDAN
Filed: 16 Jun 20
Utility
Aripiprazole Formulations Having Increased Injection Speeds
16 Sep 20
The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Magali B. Hickey, Jennifer Vandiver
Filed: 31 May 20
Utility
Opioid agonist antagonist combinations
31 Aug 20
Daniel Deaver, Elliot Ehrich
Filed: 12 Dec 18
Utility
Pharmaceutical Compositions Having Improved Storage Stability
26 Aug 20
The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent
Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver, Michael J. Palmieri, JR., Zhengzheng Pan
Filed: 29 Mar 20
Utility
Morphan and morphinan analogues, and methods of use
24 Aug 20
The present application relates to analogues of morphan and morphinan, compositions thereof, and methods for treating a disease or condition comprising administering an effective amount of the compounds or compositions to a subject in need thereof.
Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
Filed: 24 Mar 19
Utility
Methods for treating depressive symptoms
10 Aug 20
The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof.
Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
Filed: 10 Feb 19